1. Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer
   Hisao Imai et al, 2016, Thoracic Cancer CrossRef
2. Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry
   Satoshi Igawa et al, 2020, Lung Cancer CrossRef
3. CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY
   Karla Hernandez-Villafuerte et al, 2018, International Journal of Technology Assessment in Health Care CrossRef
4. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations
   null null et al, 2018, Cancer Chemotherapy and Pharmacology CrossRef
5. Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
   Sean Khozin et al, 2019, Cancer CrossRef
6. Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
   Hisao Imai et al, 2019, Thoracic Cancer CrossRef
7. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer
   Yosuke Miura et al, 2018, Medical Oncology CrossRef
8. Surrogate endpoints for overall survival in lung cancer trials: a review
   Frédéric Fiteni et al, 2017, Expert Review of Anticancer Therapy CrossRef
9. Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors
   Li Wenfeng et al, 2019, Journal of Cancer Research and Therapeutics CrossRef
10. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer
    Sandra D. Griffith et al, 2019, Advances in Therapy CrossRef
11. A model to predict the prognosis of diffuse large B-cell lymphoma based on ultrasound images
    Wenjuan Lu et al, 2023, Scientific Reports CrossRef
12. Clinical significance of post‐progression survival in lung cancer
    Hisao Imai et al, 2017, Thoracic Cancer CrossRef
13. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set
    Sandra D. Griffith et al, 2019, JCO Clinical Cancer Informatics CrossRef
14. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
    Hisao Imai et al, 2016, Canadian Respiratory Journal CrossRef
15. Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
    Junlong Li et al, 2018, BMJ Open CrossRef
16. The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer
    Satoshi Igawa et al, 2020, Haigan CrossRef
17. Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
    Yosuke Yoshida et al, 2021, Pharmaceutical Medicine CrossRef